Exploring the Mechanism of Ara-C Resistance in Acute Myeloid Leukemia
2010-04-21
Loading...
View/Download File
Persistent link to this item
Statistics
View StatisticsJournal Title
Journal ISSN
Volume Title
Title
Exploring the Mechanism of Ara-C Resistance in Acute Myeloid Leukemia
Alternative title
Authors
Published Date
2010-04-21
Publisher
Type
Presentation
Abstract
Acute myeloid leukemia (AML) is the most common and most deadly type of leukemia in adults, affecting approximately 3 people per 100,000. AML is typically treated with a cocktail of chemotherapeutic drugs, most often involving the pharmaceutical agent cytosinearabinoside (Ara-C). Treatment with Ara-C will almost always cause remission in AML patients. However, developed resistance to Ara-C becomes a problem for many patients suffering from the disease, and many relapse within a few years of remission. We are using an in vitro system to model the Ara-C resistance in AML cell lines.
Description
Additional contributors: Susan K. Rathe; David A. Largaespada (faculty mentor)
Related to
Replaces
License
Series/Report Number
Funding information
Funding for this project was provided by The Leukemia and Lymphoma Society (grant 7019-04).
Isbn identifier
Doi identifier
Previously Published Citation
Other identifiers
Suggested citation
Ellingson, Alexandra M.. (2010). Exploring the Mechanism of Ara-C Resistance in Acute Myeloid Leukemia. Retrieved from the University Digital Conservancy, https://hdl.handle.net/11299/62360.
Content distributed via the University Digital Conservancy may be subject to additional license and use restrictions applied by the depositor. By using these files, users agree to the Terms of Use. Materials in the UDC may contain content that is disturbing and/or harmful. For more information, please see our statement on harmful content in digital repositories.